A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Active, not recruitingOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Neovascular Age-related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)

Interventions

DRUG

Aflibercept (Eylea, BAY86-5321)

8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).

Trial Locations (1)

Bayer, Osaka